Cancer immunotherapy against head and neck cancer which targeting immune checkpoint ligand; PD-L1
| Project/Area Number |
16H06609
|
|---|
| Research Category |
Grant-in-Aid for Research Activity Start-up
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Otorhinolaryngology
|
|---|
| Research Institution | Asahikawa Medical College |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2016-08-26 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
Fiscal Year 2017: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | 頭頸部癌 / 腫瘍免疫 / 免疫チェックポイント分子 / PD-L1 / 癌ワクチン療法 / ヘルパーT細胞 / 癌 / 癌免疫療法 / 免疫学 |
|---|
| Outline of Final Research Achievements |
Recently, anti-programmed cell death-1 monoclonal antibody has yielded good clinical responses in recurrent and/or metastatic HNSCC patients. Therefore, programmed death-ligand 1 (PD-L1) may be a favorable target molecule for cancer immunotherapy. Furthermore, PD-L1-expressing malignant cells could be targeted by PD-L1-specific CD8+ cytotoxic T lymphocytes. However, it remains unclear whether CD4+ helper T lymphocytes (HTLs) recognize and kill tumor cells in a PD-L1-specific manner. Therefore, in this study, we designed an MHC class II binding peptide PD-L1241-265 using computer-based algorithms and assessed its potential to activate CD4+ HTLs from peripheral blood of healthy donors. PD-L1241-265-specific HTLs showed not only cytokine production but also cytotoxicity against tumor cells in a PD-L1-dependent manner and significantly inhibited growth of PD-L1-expressing human tumor cell lines after adoptive transfer into immunodeficient mice.
|
Report
(3 results)
Research Products
(9 results)
